Suter F - Search Results

1

Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.

Maggiolo F, Roat E, Pinti M, Nasi M, Gibellini L, De Biasi S, Airoldi M, Ravasio V, Mussini C, Suter F, Cossarizza A. Maggiolo F, et al. Among authors: suter f. Antivir Ther. 2010;15(1):51-9. doi: 10.3851/IMP1483. Antivir Ther. 2010. PMID: 20167991 Clinical Trial.

2

Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.

Maggiolo F, Callegaro A, Arici C, Quinzan G, Gregis G, Ripamonti D, Tebaldi A, Goglio A, Suter F. Maggiolo F, et al. Among authors: suter f. Antivir Ther. 2003 Apr;8(2):121-6. Antivir Ther. 2003. PMID: 12741624 Clinical Trial.

3

Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients.

Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Arici C, Ravasio L, Suter F. Maggiolo F, et al. Among authors: suter f. Antivir Ther. 2003 Aug;8(4):339-46. Antivir Ther. 2003. PMID: 14518703 Clinical Trial.

4

Once-a-day HAART: dream or reality?

Maggiolo F, Ripamonti D, Suter F. Maggiolo F, et al. Among authors: suter f. HIV Clin Trials. 2003 May-Jun;4(3):193-201. doi: 10.1310/1ger-1qjg-wdxm-489u. HIV Clin Trials. 2003. PMID: 12815559 Review.

5

Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients.

Ripamonti D, Arici C, Pezzotti P, Maggiolo F, Ravasio L, Suter F. Ripamonti D, et al. Among authors: suter f. AIDS. 2004 Jan 23;18(2):334-7. doi: 10.1097/00002030-200401230-00028. AIDS. 2004. PMID: 15075556

6

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.

Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Maggiolo F, et al. Among authors: suter f. AIDS. 2004 Feb 20;18(3):439-46. doi: 10.1097/00002030-200402200-00010. AIDS. 2004. PMID: 15090796 Clinical Trial.

7

Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, Airoldi M, Suter F. Maggiolo F, et al. Among authors: suter f. Clin Infect Dis. 2005 Jan 1;40(1):158-63. doi: 10.1086/426595. Epub 2004 Dec 6. Clin Infect Dis. 2005. PMID: 15614706

8

Quadruple-drug induction HAART in advanced HIV infection.

Maggiolo F, Ripamonti D, Callegaro A, Gregis G, Quinzan G, Suter F. Maggiolo F, et al. Among authors: suter f. HIV Clin Trials. 2005 Jan-Feb;6(1):1-4. doi: 10.1310/LBGE-NMMX-CE1A-AK0Y. HIV Clin Trials. 2005. PMID: 15765306 Clinical Trial.

9

Switch strategies in patients on effective HAART.

Maggiolo F, Ripamonti D, Suter F. Maggiolo F, et al. Among authors: suter f. J Antimicrob Chemother. 2005 Jun;55(6):821-3. doi: 10.1093/jac/dki119. Epub 2005 Apr 22. J Antimicrob Chemother. 2005. PMID: 15849261

10

Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.

Maggiolo F, Arici C, Airoldi M, Ripamonti D, Quinzan G, Gregis G, Ravasio V, Bombana E, Suter F. Maggiolo F, et al. Among authors: suter f. J Antimicrob Chemother. 2007 Mar;59(3):569-72. doi: 10.1093/jac/dkl534. Epub 2007 Jan 25. J Antimicrob Chemother. 2007. PMID: 17255141

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

264 results

Search Page

Filters